Hal Sternberg Net Worth

Hal Sternberg biography

Dr. Hal Sternberg Ph.D. serves as Vice President - Research of the Company. Prior to serving in that role, Dr. Sternberg was Vice President of Research of Lineage for over 25 years and was one of Lineage co-founders. Prior to co-founding and joining Lineage, Dr. Sternberg held various positions at the University of California at Berkeley from 1982 to 1988, where he supervised a team of researchers studying Alzheimer’s Disease. Dr. Sternberg holds a M.S. in Chemistry and Ph.D. in Biochemistry from the University of Maryland.

What is the salary of Hal Sternberg?

As the Vice President - Research of AgeX Therapeutics Inc, the total compensation of Hal Sternberg at AgeX Therapeutics Inc is $329,023. There are 5 executives at AgeX Therapeutics Inc getting paid more, with Michael West having the highest compensation of $1,041,700.

How old is Hal Sternberg?

Hal Sternberg is 66, he's been the Vice President - Research of AgeX Therapeutics Inc since 2017. There are 3 older and 7 younger executives at AgeX Therapeutics Inc. The oldest executive at AgeX Therapeutics Inc is Judith Segall, 68, who is the Sec..

What's Hal Sternberg's mailing address?

Hal's mailing address filed with the SEC is 1101 MARINA VILLAGE PARKWAY, SUITE 201, , ALAMEDA, CA, 94501.

Insiders trading at AgeX Therapeutics Inc

Over the last 6 years, insiders at AgeX Therapeutics Inc have traded over $0 worth of AgeX Therapeutics Inc stock and bought 23,000 units worth $15,440 . The most active insiders traders include Gregory Bailey, Michael D West a Judith Segall. On average, AgeX Therapeutics Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,024. The most recent stock trade was executed by Michael D West on 11 March 2023, trading 3,125 units of AGE stock currently worth $34,688.

What does AgeX Therapeutics Inc do?

agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha

AgeX Therapeutics Inc executives and stock owners

AgeX Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael West,
  Chief Executive Officer, Founder, Director
• Dr. Michael D. West Ph.D.,
  Founder, Pres, CEO & Director
• Dr. Michael D. West,
  Founder, Pres, CEO & Director
• Nafees Malik,
  Chief Operating Officer
• Gregory Bailey,
  Independent Chairman of the Board
• Hal Sternberg,
  Vice President - Research
• Dr. Nafees Naseer Malik M.D.,
  Chief Operating Officer
• Eun-Jae Park CPA,
  Chief Financial Officer
• Michael May,
  Independent Director
• Annalisa Jenkins,
  Independent Director
• Andrea Park,
  Chief Financial Officer
• Judith Segall,
  Sec.
• Dr. Ivan Labat,
  Chief Information Officer
• Andrea Eun-Jae Park CPA,
  Chief Financial Officer
• Judith Segall,
  Director of Admin & Secretary
• Ltd Juvenescence,
  Director
• John F Mauldin,
  Director
• Michael H. Mulroy,
  Director
• Joanne M. Hackett,
  Director